Y
Yasuhiko Nishioka
Researcher at University of Tokushima
Publications - 284
Citations - 8237
Yasuhiko Nishioka is an academic researcher from University of Tokushima. The author has contributed to research in topics: Lung cancer & Internal medicine. The author has an hindex of 43, co-authored 254 publications receiving 7124 citations. Previous affiliations of Yasuhiko Nishioka include François Rabelais University & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
Seiji Yano,Wei Wang,Qi Li,Kunio Matsumoto,Haruko Sakurama,Takahiro Nakamura,Hirokazu Ogino,Soji Kakiuchi,Masaki Hanibuchi,Yasuhiko Nishioka,Hisanori Uehara,Tetsuya Mitsudomi,Yasushi Yatabe,Toshikazu Nakamura,Saburo Sone +14 more
TL;DR: In this article, the authors showed that hepatocyte growth factor (HGF), a ligand of MET oncoprotein, induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring the phosphatidylinositol 3-kinase/Akt signaling pathway via phosphorylation of MET, but not EGFR or ErbB3.
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
Seiji Yano,Wei Wang,Qi Li,Kunio Matsumoto,Haruko Sakurama,Takahiro Nakamura,Hirokazu Ogino,Soji Kakiuchi,Masaki Hanibuchi,Yasuhiko Nishioka,Hisanori Uehara,Tetsuya Mitsudomi,Yasushi Yatabe,Toshikazu Nakamura,Saburo Sone +14 more
TL;DR: It is shown that hepatocyte growth factor (HGF), a ligand of MET oncoprotein, induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring the phosphatidylinositol 3-kinase/Akt signaling pathway via phosphorylation of MET, but not EGFR or ErbB3.
Journal ArticleDOI
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL‐1α
Hitoe Torisu,Mayumi Ono,Hiromaro Kiryu,Masutaka Furue,Yasukazu Ohmoto,Juichiro Nakayama,Yasuhiko Nishioka,Saburo Sone,Michihiko Kuwano +8 more
TL;DR: Direct evidence is found that production of the potent angiogenic factors IL‐8 and VEGF from melanoma cells is up‐regulated through TNFα and/or IL‐1α secreted by activated monocytes/macrophages, influencing both tumor growth and angiogenesis in melanomas.
Journal ArticleDOI
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Athol U. Wells,Kevin R. Flaherty,Kevin K. Brown,Yoshikazu Inoue,Anand Devaraj,Luca Richeldi,Teng Moua,Bruno Crestani,Wim A. Wuyts,Susanne Stowasser,Manuel Quaresma,Rainer Georg Goeldner,Rozsa Schlenker-Herceg,Martin Kolb,S. Abe,Myriam Aburto,O. Acosta,C. Andrews,Danielle Antin-Ozerkis,G. Arce,M. Arias,Sergey Avdeev,A. Barczyk,Rebecca Bascom,E. Bazdyrev,Paul Beirne,E. Belloli,M. A. Bergna,E. Bergot,Nitin Y. Bhatt,S. Blaas,Benjamin Bondue,Francesco Bonella,E. Britt,Ketan P. Buch,J. Burk,H. Cai,A. Cantin,D. M. Castillo Villegas,A. Cazaux,S. Cerri,S. Chaaban,Nazia Chaudhuri,Vincent Cottin,B. Crestani,G. Criner,Caroline Dahlqvist,Sonye K. Danoff,J. Dematte D'Amico,Daniel F. Dilling,P. Elias,Neil Ettinger,J. Falk,E. R. Fernández Pérez,A. Gamez-Dubuis,G. Giessel,A. Gifford,Marilyn K. Glassberg,C. Glazer,J. Golden,L. Gómez Carrera,Julien Guiot,R. Hallowell,H. Hayashi,J. Hetzel,Nik Hirani,L. Homik,Ben Hope-Gill,D. Hotchkin,K. Ichikado,M. Ilkovich,Y. Inoue,S. Izumi,E. Jassem,L. Jones,Stéphane Jouneau,Robert J. Kaner,J. Kang,T. Kawamura,Romain Kessler,Y. Kim,K. Kishi,H. Kitamura,M. Kolb,Y. Kondoh,C. Kono,D Koschel,Michael Kreuter,Tejaswini Kulkarni,J. Kus,F. Lebargy,A. León Jiménez,Q. Luo,Yolanda Mageto,Toby M. Maher,S. Makino,Sylvain Marchand-Adam,C. Marquette,R. Martinez,M. Martínez,R. Maturana Rozas,Y. Miyazaki,Sergey Moiseev,Maria Molina-Molina,Lake Morrison,L. Morrow,T. Moua,Anoop M. Nambiar,Yasuhiko Nishioka,Hilario Nunes,M. Okamoto,Justin M. Oldham,Maria Otaola,Maria Padilla,J. S. Park,Nina Patel,Alberto Pesci,W. Piotrowski,L. Pitts,H. Poonyagariyagorn,Antje Prasse,Silvia Quadrelli,W. Randerath,R. Refini,M. Reynaud-Gaubert,F. Riviere,J. A. Rodríguez Portal,Ivan O. Rosas,M. Rossman,Zeenat Safdar,T. Saito,N. Sakamoto,M. Salinas Fénero,J. Sauleda,Shelley L. Schmidt,Mary Beth Scholand,M. Schwartz,Shane Shapera,Oksana A. Shlobin,B. Sigal,A. Silva Orellana,Dirk Skowasch,J. W. Song,S. Stieglitz,Helen Stone,Mary E. Strek,T. Suda,H. Sugiura,H. Takahashi,H. Takaya,T. Takeuchi,Krishna Thavarajah,Leslie Tolle,S. Tomassetti,K. Tomii,Claudia Valenzuela,Carlo Vancheri,F. Varone,Srihari Veeraraghavan,A. Villar,S. Weigt,L. Wemeau,W. Wuyts,Z. Xu,V. Yakusevich,Y. Yamada,H. Yamauchi,D. Ziora +167 more
TL;DR: The INBUILD trial suggests that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis.
Journal ArticleDOI
Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Wei Wang,Qi Li,Tadaaki Yamada,Kunio Matsumoto,Isao Matsumoto,Makoto Oda,Go Watanabe,Yoshiyuki Kayano,Yasuhiko Nishioka,Saburo Sone,Seiji Yano +10 more
TL;DR: Combined use of gefitinib plus anti-HGF antibody or the HGF antagonist, NK4, successfully overcame the fibroblast-induced EGFR-TKI resistance both in vitro and in vivo and indicates that crosstalk to stromal fibroblasts plays a critical role in lung cancer resistance to EG FR-TKIs.